| Medical and Health Sciences | Lifetime | 232 | GB 27 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 42 | GB 5 | 99.99 |
| Cardiology and Cardiovascular Medicine | Lifetime | 48 | GB 5 | 99.96 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 38 | GB 6 | 99.87 |
| Pulmonary and Respiratory Medicine | Lifetime | 564 | GB 41 | 99.20 |
| Complementary and Alternative Medicine | Lifetime | 617 | GB 54 | 95.30 |
| Nephrology | Lifetime | 751 | GB 41 | 89.01 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 18 | GB 3 | 99.92 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 15 | GB 3 | 99.91 |
| Surgery | 2021-2025 | 284 | GB 14 | 98.16 |
| Econometrics and Quantitative Economics | 2021-2025 | 816 | GB 65 | 94.78 |
| Epidemiology | 2021-2025 | 682 | GB 60 | 93.55 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 612 | GB 37 | 92.88 |
| Nephrology | 2021-2025 | 209 | GB 11 | 89.07 |
| Heart Failure Treatment and Management | Lifetime | 9 | GB 1 | 99.94 |
| Hormonal Regulation and Hypertension | Lifetime | 7 | GB 1 | 99.87 |
| Cardiovascular Function and Risk Factors | Lifetime | 48 | GB 2 | 99.90 |
| Electrolyte and hormonal disorders | Lifetime | 11 | GB 1 | 99.69 |
| Blood Pressure and Hypertension Studies | Lifetime | 31 | GB 4 | 99.80 |
| Diabetes Treatment and Management | Lifetime | 33 | GB 4 | 99.82 |
| Potassium and Related Disorders | Lifetime | 6 | GB 1 | 99.82 |
| GDF15 and Related Biomarkers | Lifetime | 4 | GB 1 | 99.37 |
| Cardiac Fibrosis and Remodeling | Lifetime | 30 | GB 2 | 99.32 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 202 | GB 33 | 99.35 |
| Pancreatic function and diabetes | Lifetime | 245 | GB 27 | 99.13 |
| Cardiac pacing and defibrillation studies | Lifetime | 190 | GB 7 | 99.34 |
| Heart Rate Variability and Autonomic Control | Lifetime | 493 | GB 39 | 98.35 |
| Cardiovascular Health and Disease Prevention | Lifetime | 353 | GB 30 | 98.28 |
| Lipoproteins and Cardiovascular Health | Lifetime | 469 | GB 47 | 98.07 |
| Heart rate and cardiovascular health | Lifetime | 31 | GB 2 | 97.86 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 962 | GB 58 | 97.89 |
| Peptidase Inhibition and Analysis | Lifetime | 990 | GB 58 | 96.99 |
| Hemodynamic Monitoring and Therapy | Lifetime | 597 | GB 55 | 96.83 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 373 | GB 27 | 96.59 |
| Mechanical Circulatory Support Devices | Lifetime | 816 | GB 38 | 97.04 |
| Cardiovascular and exercise physiology | Lifetime | 924 | GB 87 | 96.62 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | Lifetime | 285 | GB 27 | 94.17 |
| Pharmaceutical Economics and Policy | Lifetime | 590 | GB 73 | 93.97 |
| Pharmacology and Obesity Treatment | Lifetime | 838 | GB 82 | 92.00 |
| Health and Medical Research Impacts | Lifetime | 976 | GB 102 | 86.45 |
| Vagus Nerve Stimulation Research | Lifetime | 575 | GB 25 | 85.09 |
| Vitamin K Research Studies | Lifetime | 906 | GB 64 | 82.28 |
| Pancreatic function and diabetes | 2021-2025 | 7 | GB 1 | 99.81 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 25 | GB 4 | 99.85 |
| Diabetes Treatment and Management | 2021-2025 | 17 | GB 4 | 99.85 |
| Heart Failure Treatment and Management | 2021-2025 | 15 | GB 3 | 99.87 |
| Hormonal Regulation and Hypertension | 2021-2025 | 9 | GB 2 | 99.62 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 147 | GB 26 | 98.10 |
| Potassium and Related Disorders | 2021-2025 | 13 | GB 2 | 99.00 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 107 | GB 9 | 98.56 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 74 | GB 8 | 97.51 |
| GDF15 and Related Biomarkers | 2021-2025 | 15 | GB 4 | 93.42 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 200 | GB 17 | 96.36 |
| Health and Medical Research Impacts | 2021-2025 | 47 | GB 2 | 91.59 |
| Electrolyte and hormonal disorders | 2021-2025 | 47 | GB 2 | 94.88 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 186 | GB 16 | 95.58 |
| Diabetes Management and Research | 2021-2025 | 456 | GB 54 | 94.89 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 348 | GB 15 | 93.28 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 814 | GB 34 | 87.75 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 141 | GB 18 | 87.07 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 763 | GB 40 | 83.68 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 91 | GB 8 | 78.80 |
| Diet, Metabolism, and Disease | 2021-2025 | 973 | GB 31 | 80.72 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 859 | GB 25 | 77.07 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 446 | GB 28 | 77.19 |
| Medication Adherence and Compliance | 2021-2025 | 542 | GB 30 | 77.56 |
| Statistical Methods in Clinical Trials | 2021-2025 | 497 | GB 74 | 78.63 |
| Adenosine and Purinergic Signaling | 2021-2025 | 455 | GB 16 | 74.10 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 560 | GB 8 | 71.00 |
| Ion Transport and Channel Regulation | 2021-2025 | 541 | GB 15 | 60.90 |
| Heart rate and cardiovascular health | 2021-2025 | 164 | GB 5 | 49.02 |
| Sex and Gender in Healthcare | 2021-2025 | 673 | GB 64 | 43.91 |
| Neurological and metabolic disorders | 2021-2025 | 820 | GB 22 | 36.61 |
| Apelin-related biomedical research | 2021-2025 | 771 | GB 23 | 31.45 |
